London (Reuters) – Industrie Produktivit\u00e4t<\/p>\n
pharmakologische schlie\u00dflich nach Jahren verbessern<\/p>\n
T\u00e4uschung in der Forschung, in Momenten, in denen die<\/p>\n
Labors wenden ihre Aufmerksamkeit von Massenm\u00e4rkten in Richtung<\/p>\n
der Schaffung von Arzneimitteln f\u00fcr weitere seltsamen Krankheiten und mit<\/p>\n
nur wenige therapeutische Optionen.<\/p>\n
Thomson Reuters Daten ver\u00f6ffentlicht am Dienstag zeigte, dass<\/p>\n
Weitere neue Medikamente erreichen den Markt und die der<\/p>\n
Industrie genossen hat bessere Rate des Erfolges in der<\/p>\n
teure klinische Entwicklung. Endstufe<\/p>\n
die innovative Medikamente oder neue Entit\u00e4ten <\/p>\n
Molekulare, weltweit im Jahr 2011 ins Leben gerufen, es erreicht maximal<\/p>\n<\/p>\n
ein Jahrzehnt der 31, oberhalb der 21 2010.<\/p>\n
geh\u00f6ren Einnahmen, die der Markt im vergangenen Jahr<\/p>\n
Fortschritte significant as new treatments Roche and<\/p>\n
Bristol-Myers Squibb for melanoma, the first drug<\/p>\n
new for lupus in half a century of GlaxoSmithKline, and two<\/p>\n
new drugs for hepatitis C of Merck and Vertex<\/p>\n
Pharmaceuticals.<\/p>\n
panorama is also improving for the next wave of<\/p>\n
products, since the amount of experimental drugs<\/p>\n
for which last year was requested approval of the<\/p>\n
regulators – last obstacle to reach a market – nearly<\/p>\n
doubled the level of 2007.<\/p>\n
in addition, the amount of drugs that failed in the stage<\/p>\n
clinical – trials phase III – final fell sharply, to 45<\/p>\n
in the past three years from 54 between 2008 and 2010, according to<\/p>\n
registration research and development pharmaceutical of the 2012<\/p>\n
drive CMR International of Thomson Reuters.<\/p>\n
the Industria global de Productos Farmac\u00e9uticos, Que Gener\u00f3<\/p>\n
Ventas R\u00e9cord Por 880.000 Millones de D\u00f3lares de el A\u00fan 2011 keine<\/p>\n
Cuenta Con la Cantidad de F\u00e1rmacos ascenseurs Abs. Reemplazar ein<\/p>\n
Los Que Est\u00e1n Enfrentando Competencia Gen\u00e9rica de lo Que es la<\/p>\n
B\u00fcrgermeister Ola de Expiraciones de Patentes De La Historia.<\/p>\n
No Obstante, la Informaci\u00f3n Pinta un Panorama M\u00e1s Alentador<\/p>\n
Para Una Industria Que ha Sabido Exasperar a Los Inversores al<\/p>\n
Lograr Convertir Decenas de Meilen de Millones de D\u00f3lares de<\/p>\n
Investigaci\u00f3n de Una Serie de Nuevos Productos Confiables.<\/p>\n
Con Todo, kein Se Recuperar\u00e1 la Fuerza De La Noche a la<\/p>\n
Ma\u00f1ana, ya Que Los Retornos De La Industria Por Investigaci\u00f3n y<\/p>\n
Desarrollo (R&D Por Su Sigla En alem\u00e1n) Casi Se Redujeron a la<\/p>\n
Mitad Entre 1990 y el 2010, Seg\u00fan un An\u00e1lisis de Octubre de<\/p>\n
KPMG.<\/p>\n
MENOS CANTIDAD, M\u00c1S CALIDAD<\/p>\n
“”There has clearly been a downward trend in the<\/p>\n
efficiency in R & D in the past, but what we are seeing now<\/p>\n
is some indicators that would be reverting”, said Chris<\/p>\n
McKenna, Vice President of services of Thomson<\/p>\n
Reuters Life Sciences.<\/p>\n
“production of new molecular entities is improving and<\/p>\n
is the number of projects that come into clinical development<\/p>\n
decreasing, which indicates that the industry is abandoning the<\/p>\n
game of numbers and it is approaching candidates best<\/p>\n
quality (…) will probably need a couple of more years<\/p>\n
to see if it is a sustained pattern”, added.<\/p>\n
R & D expenditures on prescription drugs is<\/p>\n
stabilized in the last four years, after decades of<\/p>\n
increases sustained. CMR data show that the<\/p>\n
leading laboratories spent an aggregate of 71.050 total<\/p>\n
million dollars in 2011.<\/p>\n
that was 2.5 percent more than in 2010, although part<\/p>\n
boost responded to the weakness of the dollar, since much<\/p>\n
of money in R & D globally is spent in euros and francs<\/p>\n
Swiss.<\/p>\n
pharmacological companies are currently adopting<\/p>\n
approaches to R & D much tighter spending, reducing their<\/p>\n
budgets and relocating resources in areas more promising.<\/p>\n
the pace of budget R & d cuts varies<\/p>\n
significantly between laboratories. Pfizer and AstraZeneca are<\/p>\n
facing losses of patents more hard and they are also<\/p>\n
making the biggest cuts.<\/p>\n
that leaves Novartis and Roche dominating the table of expenditure in<\/p>\n
R & D. Novartis is the largest single investor in this area, with<\/p>\n
a budget of 9,000 million dollars.<\/p>\n
Roche und Novartis sind leistungsf\u00e4hige Teilnehmer im Bereich der<\/p>\n
Krebs, Drogenbereich, die die gr\u00f6\u00dfte anzieht<\/p>\n
Investitionen aller Kategorien therapeutische.<\/p>\n
auf der anderen Seite, das Volumen der Entwicklungen \u00fcber neue Drogen<\/p>\n
Herz-Kreislauf- und nerv\u00f6sen System – zwei Bereiche die in der<\/p>\n
Vergangenheit trug mit f\u00fchrenden Unternehmen im Vertrieb als Statine<\/p>\n
Cholesterin und Antidepressiva–steuern sie fielen mehr<\/p>\n
F\u00fcnftel.<\/p>\n","protected":false},"excerpt":{"rendered":"
London (Reuters) – Industrie Produktivit\u00e4t pharmakologische schlie\u00dflich nach Jahren verbessern T\u00e4uschung in der Forschung, in Momenten, in denen die Labors wenden ihre Aufmerksamkeit von Massenm\u00e4rkten in Richtung der Schaffung von Arzneimitteln f\u00fcr weitere seltsamen Krankheiten und mit nur wenige therapeutische Optionen. Thomson Reuters Daten ver\u00f6ffentlicht am Dienstag zeigte, dass Weitere neue Medikamente erreichen den Markt […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-26772","post","type-post","status-publish","format-standard","hentry","category-allgemeine","et-doesnt-have-format-content","et_post_format-et-post-format-standard"],"_links":{"self":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/26772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/comments?post=26772"}],"version-history":[{"count":0,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/26772\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/media?parent=26772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/categories?post=26772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/tags?post=26772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}